Director Gottlieb Scott sold $1,359,989 worth of shares (27,838 units at $48.85), decreasing direct ownership by 31% to 60,676 units (SEC Form 4)

$TEM
Computer Software: Programming Data Processing
Technology
Get the next $TEM alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gottlieb Scott

(Last) (First) (Middle)
C/O TEMPUS AI, INC.
600 WEST CHICAGO AVENUE, SUITE 510

(Street)
CHICAGO IL 60654

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tempus AI, Inc. [ TEM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 03/17/2025 S(1) 4,612 D $46.59(2) 83,902 D
Class A Common Stock 03/17/2025 S(1) 3,077 D $47.53(3) 80,825 D
Class A Common Stock 03/17/2025 S(1) 6,349 D $48.44(4) 74,476 D
Class A Common Stock 03/17/2025 S(1) 6,698 D $49.72(5) 67,778 D
Class A Common Stock 03/17/2025 S(1) 7,102 D $50.45(6) 60,676 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 27, 2024, and was made in part to cover applicable tax obligations arising in connection with the vesting and settlement of restricted stock units.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.06 to $47.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6).
3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.08 to $48.00 inclusive.
4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.08 to $49.07 inclusive.
5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.12 to $50.11 inclusive.
6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.12 to $50.81 inclusive.
/s/ Andrew Polovin, Attorney-in-Fact 03/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $TEM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TEM

DatePrice TargetRatingAnalyst
2/25/2025$50.00 → $55.00Overweight → Neutral
Analyst
2/12/2025Outperform → Mkt Perform
William Blair
2/5/2025$58.00 → $74.00Buy
TD Cowen
12/13/2024$60.00Outperform
Wolfe Research
12/9/2024$74.00Buy
Guggenheim
11/11/2024$45.00 → $65.00Buy → Hold
Stifel
10/2/2024$45.00 → $60.00Buy → Neutral
BofA Securities
8/12/2024$40.00Neutral
Piper Sandler
More analyst ratings

$TEM
Press Releases

Fastest customizable press release news feed in the world

See more
  • Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology (ACC) Annual Meeting, which convenes from March 29-31 in Chicago, Illinois. This is the first year that Tempus is presenting research, all of which highlights the application of AI to support clinicians in delivering personalized care. "Tempus is committed to enabling clinicians to provide better, guideline-recommended care to patients who may have undiagnosed or undertreated cardiovascular disease," said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiolog

    $TEM
    Computer Software: Programming Data Processing
    Technology
  • Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7-10, 2025. Tempus' Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Wednesday, April 9. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides

    $TEM
    Computer Software: Programming Data Processing
    Technology
  • Tempus Announces Acquisition of Deep 6 AI

    Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus' existing network Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate recruitment, and generate real-world evidence (RWE) with speed and precision. Its AI-powered software matches patients to clinical trials by mining real-time structured and unstructured

    $TEM
    Computer Software: Programming Data Processing
    Technology

$TEM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TEM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TEM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TEM
SEC Filings

See more

$TEM
Financials

Live finance-specific insights

See more
  • Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i

    $TEM
    Computer Software: Programming Data Processing
    Technology
  • Tempus to Report Third Quarter 2024 Financial Results on November 4

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the

    $TEM
    Computer Software: Programming Data Processing
    Technology
  • Tempus to Report Third Quarter 2024 Financial Results on November 7

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7177136 Domestic Dial-in Number: (800) 715-9871 International Dial-in

    $TEM
    Computer Software: Programming Data Processing
    Technology

$TEM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more